The role of MDCT and MRI in the diagnosis of focal liver diseases
https://doi.org/10.16931/1995-5464.2019491-110
Abstract
Despite the great technical achievements in the field of tomographic examinations (CT, MRI), the problem of differentiation of focal liver lesions cannot always be solved only in a non-invasive way. At the same time, MRI with a hepatospecific agent, gadoxetic acid, can solve many problems, primarily related to the diagnosis of liver metastases and monitoring of nodules in cirrhotic liver.
The aim. To show the advantages of MRI with hepatobiliary MRI contrast agents as the final phase of non-invasive diagnosis of focal liver lesions.
Material and methods. Abstracts of 183 scientific articles (2010–2019) were selected in the PubMed information and analytical system for the keywords “focal liver lesion” and “gadoxetic acid”. Articles about special aspects of MRI examination or general information were excluded. 29 full-text articles were selected for analysis.
Results. The analysis data are grouped in three categories as “diagnosis of liver metastases”, “diagnosis of HCC against the background of normal hepatic parenchyma”, “MRI diagnosis of HCC against the background of cirrhosis”.
Conclusion. The main achievement of MRI diagnostics with gadoxetic acid is the differentiation of small focal liver lesions, including metastases, regenerative nodes, dysplastic nodes, and highly differentiated HCC. This allows you to increasingly avoid invasive methods in the diagnosis of focal liver lesions. Integrated MRI technologies (MRI-DVI and MRI with gadoxetic acid) are currently the most informative, safe and in demand. In MRI with hepatobiliary contrast agents, the intensity of the HCC signal in the hepatospecific phase is considered as an imaging tumor biomarker. Border small liver nodules are usually not hypervascular, they are hypointensive in the hepatospecific phase.
The aim. To show the advantages of MRI with hepatobiliary MRI contrast agents as the final phase of non-invasive diagnosis of focal liver lesions.
Material and methods. Abstracts of 183 scientific articles (2010–2019) were selected in the PubMed information and analytical system for the keywords “focal liver lesion” and “gadoxetic acid”. Articles about special aspects of MRI examination or general information were excluded. 29 full-text articles were selected for analysis.
Results. The analysis data are grouped in three categories as “diagnosis of liver metastases”, “diagnosis of HCC against the background of normal hepatic parenchyma”, “MRI diagnosis of HCC against the background of cirrhosis”.
Conclusion. The main achievement of MRI diagnostics with gadoxetic acid is the differentiation of small focal liver lesions, including metastases, regenerative nodes, dysplastic nodes, and highly differentiated HCC. This allows you to increasingly avoid invasive methods in the diagnosis of focal liver lesions. Integrated MRI technologies (MRI-DVI and MRI with gadoxetic acid) are currently the most informative, safe and in demand. In MRI with hepatobiliary contrast agents, the intensity of the HCC signal in the hepatospecific phase is considered as an imaging tumor biomarker. Border small liver nodules are usually not hypervascular, they are hypointensive in the hepatospecific phase.
About the Author
G. G. Karmazanovsky
А.V. Vishnevsky Nаtionаl Mediсal Reseаrсh Сenter of Surgery,
Pirogov Russian National Research Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Corresponding Member of the Russiаn Асаdemy of Sсienсes, Doсt. of Sсi. (Med.), Professor, Heаd of Rаdiology Depаrtment; Professor of Radiology Department
Phone: +7-499-236-15-37
27, B. Serpukhovskaya, Moscow, 117997, Russian Federation
house 1, Ostrivityanova str., Moscow, 115093, Russian Federation
References
1. Karmazanovsky G.G. The benefits of using high contrast media in MDCT. Medical visualization. 2013; 4: 128–133. (In Russian)
2. Stuk M.V., Osokin Ya.A., Kondrat’ev E.V., Varlamov A.V., Karmazanovskiy G.G. Contrast-enhanced computed tomography is the required minimum in the diagnosis of abdominal and retroperitoneal space-occupying lesions. J. Radiol. Nuclear Med. 2016; 97 (1): 40–47. https://doi.org/10.20862/0042-4676-
3. 2016-97-1-41-47 (In Russian)
4. Karmazanovsky G.G. Contrast-enhanced tomography as a real tool for obtaining objective information in the all possible economies. Diagnostic radiology and radiotherapy. 2016; 1: 5–12. https://doi.org/10.22328/2079-5343-2016-1-5-12 (In Russian)
5. Schwope R.B., May L.A., Reiter M.J., Lisanti C.J., Margolis D.J. Gadoxetic acid: pearls and pitfalls. Abdom. Imaging. 2015; 40 (6): 2012–2029. https://doi.org/10.1007/s00261-015-0354-7
6. Zech C.J., Korpraphong P., Huppertz A., Denecke T., Kim M.J., Tanomkiat W., Jonas E., Ba-Ssalamah A. VALUE study group. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases. Br. J. Surg. 2014; 101 (6): 613–621. https://doi.org/10.1002/bjs.9465
7. Vilgrain V., Esvan M., Ronot M., Caumont-Prim A., Aubé C., Chatellier G. A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases. Eur. Radiol. 2016; 26 (12): 4595–4615. https://doi.org/10.1007/s00330-016-4250-5
8. Colagrande S., Castellani A., Nardi C., Lorini C., Calistri L., Filippone A. The role of diffusion-weighted imaging in the detection of hepatic metastases from colorectal cancer: A comparison with unenhanced and Gd-EOB-DTPA enhanced MRI. Eur. J. Radiol. 2016; 85 (5): 1027–1034. https://doi.org/10.1016/j.ejrad.2016.02.011
9. Lee D., Cho E.S., Kim D.J., Kim J.H., Yu J.S., Chung J.J. Validation of 10-minute delayed hepatocyte phase imaging with 30° flip angle in gadoxetic acid-enhanced MRI for the detection of liver metastasis. PLoS One. 2015; 10 (10): e0139863. https://doi.org/10.1371/journal.pone.0139863
10. Neri E., Bali M.A., Ba-Ssalamah A., Boraschi P., Brancatelli G., Alves F.C., Grazioli L., Helmberger T., Lee J.M., Manfredi R., Martì-Bonmatì L., Matos C., Merkle E.M., Op De Beeck B., Schima W., Skehan S., Vilgrain V., Zech C., Bartolozzi C. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur. Radiol. 2016; 26 (4): 921–931. https://doi.org/10.1007/s00330-015-3900-3
11. Merkle E.M., Zech C.J., Bartolozzi C., Bashir M.R., Ba-Ssalamah A., Huppertz A., Lee J.M., Ricke J., Sakamoto M., Sirlin C.B., Ye S.L., Zeng M. Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. Eur. Radiol. 2016; 26 (3): 674–682. https://doi.org/10.1007/s00330-015-3873-2
12. Joo I., Lee J.M. Recent advances in the imaging diagnosis of hepatocellular carcinoma: value of gadoxetic acid-enhanced MRI. Liver Cancer. 2016; 5 (1): 67–87. https://doi.org/10.1159/000367750
13. Hwang J., Kim Y.K., Jeong W.K., Choi D., Rhim H., Lee W.J. Nonhypervascular hypointense nodules at gadoxetic acidenhanced mr imaging in chronic liver disease: diffusion-weighted imaging for characterization. Radiology. 2015; 277 (1): 309. https://doi.org/10.1148/radiol.2015154031
14. Fischer M.A., Raptis D.A., Donati O.F., Hunziker R., Schade E., Sotiropoulos G.C., McCall J., Bartlett A., Bachellier P., Frilling A., Breitenstein S., Clavien P.A., Alkadhi H., Patak M.A. MR imaging features for improved diagnosis of hepatocellular carcinoma in the non-cirrhotic liver: Multi-center evaluation. Eur. J. Radiol. 2015; 84 (10): 1879–1887. https://doi.org/10.1016/j.ejrad.2015.06.029
15. Kim B., Lee J.H., Kim J.K., Kim H.J., Kim Y.B., Lee D. The capsule appearance of hepatocellular carcinoma in gadoxetic acid-enhanced MRimaging: Correlation with pathology and dynamic CT. Medicine (Baltimore). 2018; 97 (25): e11142. https://doi.org/10.1097/MD.0000000000011142
16. Burgio M.D., Picone D., Cabibbo G., Midiri M., Lagalla R., Brancatelli G. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenatedimeglumine. Abdom. Radiol. 2016; 41 (8): 1546–1554. https://doi.org/10.1007/s00261-016-0726-7
17. Cho E.S., Choi J.Y. MRI features of hepatocellular carcinoma related to biologic behavior. Korean J. Radiol. 2015; 16 (3): 449–464. https://doi.org/10.3348/kjr.2015.16.3.449
18. Choi S.H., Lee S.S., Kim S.Y., Park S.H., Park S.H., Kim K.M., Hong S.M., Yu E., Lee M.G. Intrahepatic cholangio carcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology. 2017; 282 (3): 771–781. https://doi.org/10.1148/radiol.2016160639
19. Motosugi U., Ichikawa T., Sou H., Sano K., Tominaga L., Muhi A., Araki T. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology. 2010; 256 (1): 151–158. https://doi.org/10.1148/radiol.10091885.
20. Koh J., Chung Y.E., Nahm J.H., Kim H.Y., Kim K.S., Park Y.N., Kim M.J., Choi J.Y. Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acidenhanced MRI. Eur. Radiol. 2016; 26 (2): 407–416. https://doi.org/10.1007/s00330-015-3846-5
21. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19 (3): 329–338. https://doi.org/10.1055/s-2007-1007122
22. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., Christensen E., Pagliaro L., Colombo M., Rodés J. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 2001; 35 (3): 421–430. https://doi.org/10.1016/s0168-8278(01)00130-1
23. Bruix J., Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53 (3): 1020–1022. https://doi.org/10.1002/hep.24199
24. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56 (4): 908–943. https://doi.org/10.1016/j.jhep.2011.12.001
25. Ricke J., Seidensticker M., Mohnike K. Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: current guidelines and future prospects for radiological imaging. Liver Cancer. 2012; 1 (1): 51–58. https://doi.org/10.1159/000339020
26. Bota S., Piscaglia F., Marinelli S., Pecorelli A., Terzi E., Bolondi L. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma. Liver Cancer. 2012; 1 (3–4): 190–200. https://doi.org/10.1159/000343833
27. Belghiti J., Fuks D. Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012; 1 (2): 71–82. https://doi.org/10.1159/000342403
28. Lee Cheah Y., K.H. Chow P. Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies. Liver Cancer. 2012; 1 (3–4): 183–189. https://doi.org/10.1159/000343832
29. Chan S.C. Liver transplantation for hepatocellular carcinoma. Liver Cancer. 2013; 2 (3–4): 338–344. https://doi.org/10.1159/000343849
30. Lin S.M. Local ablation for hepatocellular carcinoma in Taiwan. Liver Cancer. 2013; 2 (2): 73–83. https://doi.org/10.1159/000343843.
31. Golfieri R., Garzillo G., Ascanio S., Renzulli M. Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acidenhanced MRI and recognition by the Western guidelines. Dig. Dis. 2014; 32 (6): 696–704. https://doi.org/10.1159/000368002
32. Cartier V., Aubé C. Gastrointestinal imaging: Tips and traps in the diagnosis of small HCC. Diagn. Interv. Imaging. 2013; 94 (7–8): 697–712. https://doi.org/10.1016/j.diii.2013.03.007
33. Motosugi U., Ichikawa T., Sou H., Sano K., Tominaga L., Muhi A., Araki T. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology. 2010; 256 (1): 151–158. https://doi.org/10.1148/radiol.10091885
34. Kim Y.K., Lee W.J., Park M.J., Kim S.H., Rhim H., Choi D. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology. 2012; 265 (1): 104–114. https://doi.org/10.1148/radiol.12112649
35. Suh C.H., Kim K.W., Pyo J., Lee J., Kim S.Y., Park S.H. Hypervascular transformation of hypovascular hypointense nodules in the hepatobiliary phase of gadoxetic acid-enhanced MRI: A systematic review and meta-analysis. AJR. 2017; 209 (4): 781–789. https://doi.org/10.2214/AJR.16.17711
36. Kim Y.K., Kim Y.K., Park H.J., Park M.J., Lee W.J., Choi D. Noncontrast MRI with diffusion-weighted imaging as the sole imaging modality for detecting liver malignancy in patients with high risk for hepatocellular carcinoma. Magn. Reson. Imaging. 2014; 32 (6): 610–618. https://doi.org/10.1016/j.mri.2013.12.021
37. Kim S.S., Kim S.H., Song K.D., Choi S.Y., Heo N.H. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study. J. Magn. Reson. Imaging. 2019; May 6. https://doi.org/10.1002/jmri.26768
38. Kozaka K., Kobayashi S., Yoneda N., Kitao A., Yoshida K., Inoue D., Ogi T., Koda W., Sato Y., Gabata T., Matsui O. Doughnut-like hyperintense nodules on hepatobiliary phase without arterial-phase hyperenhancement in cirrhotic liver: imaging and clinicopathological features. Eur. Radiol. 2019; 29 (12): 6489–6498. https://doi.org/10.1007/s00330-019-06329-y
39. Choi S.H., Lee S.S., Park S.H., Kim K.M., Yu E., Park Y., Shin Y.M., Lee M.G. LI-RADS classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI. Radiology. 2019; 290 (2): 388–397. https://doi.org/10.1148/radiol.2018181290
Review
For citations:
Karmazanovsky G.G. The role of MDCT and MRI in the diagnosis of focal liver diseases. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2019;24(4):91-110. (In Russ.) https://doi.org/10.16931/1995-5464.2019491-110
Views:
4942
Email this article 